EBR Investor Webinar: Preliminary Q2 2026 Results Discussion Regarding Reported Complications

31 July 2026

Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries ("EBR") current as at the date of this presentation. It should be read in conjunction with EBR's periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR's notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management's current expectations and beliefs. Such statements are typically identified by words such as 'may', 'could', 'believes', 'estimates', 'expects', 'anticipates', 'intends' and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR's management. EBR's results are reported under US GAAP. Certain financial data in this presentation is "non-IFRS financial information" under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR's CHESS Depositary Interests ("CDIs") are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no- action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

Building Momentum in the WiSE System

EBR has achieved several key milestones and is well positioned to continue to capitalise on its existing momentum to drive further growth. Limited market release will continue through 2026 and into 2027, with a focus on laying groundwork for broader sales coverage over time.

FDA approval received

- ✓ FDA approval received April 2025
- ✓ First and only leadless CRT device to receive FDA Pre-Market Approval
- ✓ Underpinned by Breakthrough Device Designation

Premium reimbursement

- ✓ CMS approval for NTAP (inpatient) and TPT (outpatient) at contract price of US$63,300
- ✓ CMS initiated their National Coverage Determination process

World class sales team

- ✓ Highly experienced sales team recruited from leading cardiac device companies with established physician relationships
- ✓ Sales leadership team experienced at commercialising early-stage technologies

Established commercial pathway

- ✓ Structured three-stage process from physician engagement to hospital contracting and finally, patient treatment
- ✓ Renewed focus on driving deeper utilisation in existing sites

Significant early momentum

- ✓ 117 WiSE procedures completed across US to end of Q2 2026
- ✓ Continued positive demand for WiSE with encouraging numbers of patients being identified and scheduled for H2 2026

Strategic investment in infrastructure

- ✓ New 4,751 m^2 state-of-the-art manufacturing facility in Santa Clara
- ✓ Build out completed and site qualification is underway
- ✓ Full transfer expected by end of 2026

EBR partially completed a fully underwritten A$150m capital raise, with the final $A35m underwritten tranche expected to be completed by 24 August 2026 to support its pathway to cashflow breakeven and continued US commercial scale-up.

Preliminary Q2 2026 Results

Q2’26 Key Milestones

- Partially completed a fully underwritten A$150m capital raise
  - Final $A35m underwritten tranche expected to be completed by 24 Aug 26
  - Support pathway to cashflow breakeven
- CMS initiated their National Coverage Determination process for WiSE
  - Provide broader Medicare coverage and expanded patient access
- Three major purchasing agreements signed
  - HCA Healthcare
  - Advocate Heath
  - CHRISTUS Health
- Participation at HRS2026
  - Key presentation: Real-world Outcomes from Initial US Commercial Implants
    - Reduction in complication rate down to 10% (from 19.1% in SOLVE study)

Q2’26 Commercial Progress

Limited market release starts with trained salespeople, who then engage physicians, followed by hospital contracting negotiations, leading to treated patients and revenue

Physician Engagement → Site Negotiation and Contracting → Initial Implants → Patients Treated and Revenue







These KPIs are the most important early performance indicators to predict durable commercial success

Recent Online Report of Complications

EBR Internal Investigation Completed

- MedSun report was not written by FDA, but was the hospital's report to the FDA
- EBR has completed its internal investigation without receiving any official information from the hospital and is submitting that to FDA within the required reporting window
- This complication is a known risk, but can be mitigated by following the FDA-approved transthoracic echocardiogram (TTE) procedures

Contact:

Company

Andrew Shute

Chief Corporate Development Officer

P: +44 7730 691421

E: investor.relations@ebrwise.com

Investors

Gabriella Hold

The Capital Network

P: +61 2 8999 3699

E: gaby@thecapitalnetwork.com.au

www.ebrsystemsinc.com